Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
224 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (7)
  • Currently Recruiting (3)
  • (-) Closed (4)

Medical Condition

  • Show all (997)
  • Addiction (12)
  • Allergy, Asthma, & Immunology (12)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (25)
  • Blood Disorders (18)
  • Bone & Muscle (8)
  • Cancer (93)
    • Brain Cancer (3)
    • Breast Cancer (11)
    • Gastrointestinal (2)
    • Gynecologic Cancer (29)
    • Kidney Cancer (1)
    • Leukemia (6)
    • Liver Cancer (1)
    • Lung Cancer (4)
    • Lymphoma (10)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (1)
    • Prostate Cancer (3)
    • Sarcoma (2)
    • (-) Skin Cancer (2)
      • Melanoma (2)
    • Solid Tumors (4)
  • Child Development (4)
  • COVID-19 (Coronavirus) (28)
  • Critical Illness (1)
  • Diabetes (14)
  • Ear, Nose and Throat (5)
  • Endocrine & Metabolic Disease (10)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (23)
  • Hair and Skin Disorders (2)
  • Headaches (5)
  • Healthy Volunteers (143)
  • Heart Disease (109)
  • Infectious Disease (38)
    • HIV (26)
    • (-) Lyme Disease (2)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (40)
  • Lung Disease (29)
  • Meniere's Disease (1)
  • Neurological Disorders (95)
  • Nutrition (3)
  • Obesity (1)
  • Obstetrics & Gynecology (46)
  • Pain Management (1)
  • Pediatrics (84)
  • Psychiatric Disorders (61)
  • Rehabilitation (7)
  • Stroke (5)
  • Surgery (7)
  • Transplant (33)
  • Urology (3)
  • Vascular Conditions (9)
Displaying 1 - 4 of 4

Study of Nivolumab in Patients with Resected Stage IIB/IIC Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
Read More

Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Read More

A New Treatment Study for Previously Treated Lyme Disease Patients with Persistent Fatigue

Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Closed
Are you suffering from chronic fatigue that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new treatment research study investigates whether disulfiram, commonly known as "Antabuse", has the potential to be used as a treatment option for patients experiencing chronic post-treatment Lyme symptoms. This well-known…
Read More

Meditation and Stretching for Post-Treatment Lyme Disease Syndrome

Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Closed
The CDC estimates that 10-20% of patients with Lyme disease will go on to have chronic symptoms despite having had appropriate treatment, a condition known as Post-Treatment Lyme Disease Syndrome (PTLDS). While there is currently no known cure, various therapies are being investigated. One promising approach is the practice of meditation and yoga which have…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science